Patrick Lin
Known title: Chief Business - Strategy OffCIK: 0001799363
Patrick Lin's purchase track record
How the stock did after each of Patrick Lin's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
9
of 14 since August 26, 2021
Stock higher 6 months later
11%
3 months: 14%
Median 6-month return
-35.5%
3 months: -16.0%
Beat the S&P 500
11%
median -28.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/30/2026 | PCSA | $4K | -8.3% | pending | — |
| 6/15/2026 | PCSA | $4K | -14.0% | pending | — |
| 5/29/2026 | PCSA | $4K | -19.1% | pending | — |
| 5/15/2026 | PCSA | $4K | -17.9% | pending | — |
| 4/30/2026 | PCSA | $4K | -24.4% | pending | — |
| 4/15/2026 | PCSA | $4K | -19.3% | -45.4% | +9.9% |
| 3/31/2026 | PCSA | $4K | -24.0% | -30.3% | +17.5% |
| 1/27/2025 | PCSA | $35K | -61.6% | -62.1% | +6.3% |
| 1/31/2024 | PCSA | $10K | -5.9% | -11.0% | +14.0% |
| 5/17/2022 | PCSA | $3K | +65.6% | +9.0% | -2.4% |
| 4/6/2022 | PCSA | $7K | +4.1% | -23.6% | -15.6% |
| 12/14/2021 | PCSA | $24K | -14.1% | -35.5% | -19.4% |
| 12/3/2021 | PCSA | $17K | -29.3% | -37.9% | -9.5% |
| 8/26/2021 | PCSA | $24K | -8.4% | -43.4% | -4.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PCSA | ▲ Buy | Open Market | 2,106 | $4K | 6/30/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,831 | $4K | 6/15/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,582 | $4K | 5/29/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,369 | $4K | 5/15/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,511 | $4K | 4/30/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,369 | $4K | 4/15/2026 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,603 | $4K | 3/31/2026 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 193 | $0 | 1/1/2026 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 14,482 | — | 4/1/2025 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 4,814 | $2K | 4/1/2025 | View on chart |
| PCSA | ▲ Buy | Open Market | 43,500 | $35K | 1/27/2025 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 644 | — | 7/10/2024 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 271 | $463 | 7/10/2024 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 1,675 | — | 4/5/2024 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 539 | $2K | 4/5/2024 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,500 | $4K | 2/1/2024 | View on chart |
| PCSA | ▲ Buy | Open Market | 2,500 | $6K | 1/31/2024 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 1,675 | — | 1/1/2024 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 539 | $2K | 1/1/2024 | View on chart |
| PCSA | ▲ Buy | Grant | 5,000 | $2K | 10/12/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 13,700 | $3K | 10/10/2023 | View on chart |
| PCSA | ▲ Buy | Grant | 12,500 | $10K | 2/9/2023 | View on chart |
| PCSA | ▲ Buy | Option Exercise | 7,601 | — | 8/5/2022 | View on chart |
| PCSA | ▼ Sell | Tax Withholding | 2,656 | $8K | 8/5/2022 | View on chart |
| PCSA | ▲ Buy | Open Market | 2,000 | $3K | 5/17/2022 | View on chart |
| PCSA | ▲ Buy | Open Market | 800 | $3K | 4/7/2022 | View on chart |
| PCSA | ▲ Buy | Open Market | 1,200 | $4K | 4/6/2022 | View on chart |
| PCSA | ▲ Buy | Open Market | 3,000 | $12K | 12/14/2021 | View on chart |
| PCSA | ▲ Buy | Open Market | 3,000 | $12K | 12/14/2021 | View on chart |
| PCSA | ▲ Buy | Open Market | 3,500 | $17K | 12/3/2021 | View on chart |
| PCSA | ▲ Buy | Open Market | 4,000 | $24K | 8/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Processa Files Prospectus for 306.5M Share Offering
Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.
Processa Files Prospectus for 306.5M Share Offering. Processa Pharmaceuticals filed a prospectus for an offering of 306.574 million common shares on behalf of selling shareholders. This large-scale secondary offering adds significant supply to the market, which may pressure the stock price. The company is currently trading near the lower end of its 52-week range, with technical indicators showing weakness.